Study | Disease stage | Tumor site | n | Treatment | HER2-positive rate (%) | Association with survival: Median OS in HER2-positive versus HER2-negative patients |
AVAGAST[1] | Metastatic* | Gastric, GEJ | 712 | FP with and without bevacizumab | NR | Null: 9.8 versus 10.5 months (NSS)¶ |
Europe/USA collaborationΔ[2] | Metastatic | Gastric, GEJ | 381 | Chemotherapy | 20 | Favorable: 13.9 versus 11.4 months (p = 0.047)¶ |
EXPAND[3,4] | Metastatic* | Gastric, GEJ | 679 | FP with and without cetuximab | 21 | Favorable in control arm: 14.0 versus 9.7 months (NSS) Favorable in treatment arm: 13.3 versus 9.2 months (NSS) |
REAL3[5] | Metastatic* | Gastric, GEJ, esophagus | 174 | EOC with and without panitumumab | 16 | Null: Details not reported |
ACTS-GC[6] | Operable | Gastric | 829 | Surgery with and without S-1 | 13.6 | Null: 5-year OS 64 versus 68% (NSS)¶ |
MAGIC[7] | Operable | Gastric, GEJ, esophagus | 415 | Surgery with and without ECF | 10.9 | Null: Details not reported |
INT0116[8] | Operable | Gastric, GEJ | 258 | Surgery with and without chemoradiotherapy | 10.9 | Null in control arm: 22 versus 24 months (p = 0.76) Adverse in chemoradiotherapy arm: 16 versus 44 months (p = 0.025) |
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟